Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne (PAPA) Syndrome
PAPA syndrome is a rare inherited autoinflammatory disorder that mainly affects the joints and skin. It is caused by mutations in the PSTPIP1 gene, which lead to overproduction of the inflammatory protein interleukin-1 beta (IL-1β). This excess triggers acute flares of pus-forming inflammation with no bacteria present, damaging joint structures and leaving severe scarring on the skin.
At Haute-Derma, we manage PAPA by combining systemic immunosuppressive treatment with advanced aesthetic restoration. Our aim is to shut down pus-forming flares quickly to protect joint cartilage, while also treating the acne and skin ulceration so patients can regain confidence in their appearance.
Our Approach to Treating PAPA Syndrome
Our specialists understand that PAPA causes both physical and emotional suffering, especially around puberty when acne flares severely. Our protocol centers on "locking down" IL-1, the cytokine chiefly responsible for the pus-filled lesions.
We were early to combine systemic biologic therapy with laser and non-surgical aesthetic treatments for post-inflammatory scarring. At Haute-Derma you receive an end-to-end care pathway: genetic diagnosis, control of arthritis flares, and restoration of smoother skin after ulcerative damage.
Our PAPA care pathway includes:
- PSTPIP1 gene sequencing to identify the dominant inherited mutation.
- Anti-IL-1 or anti-TNF-alpha biologic therapy to control systemic pus-forming inflammation.
- High-tech aesthetic treatment for severe acne and scarring from skin ulceration.
How We Diagnose PAPA at Haute-Derma
At Haute-Derma, diagnosis follows how the symptoms evolve with age:
- Assessing pyogenic arthritis: recognizing episodes of swollen, hot, red, painful joints that begin in early childhood, often after minor injuries. The joint fluid is full of pus, yet bacterial cultures come back negative.
- Checking for pyoderma gangrenosum (PG): watching for painful, rapidly spreading skin ulcers with a violet border, which usually appear after puberty.
- Evaluating acne: identifying severe nodulocystic acne, which readily leaves deep atrophic and hypertrophic scars if not treated properly.
- Inflammatory markers: tracking sharp rises in neutrophils and CRP during joint or skin flares.
- Molecular genetic testing: identifying the PSTPIP1 mutation to confirm the diagnosis and distinguish PAPA from common skin conditions.
How Is PAPA Syndrome Treated at Haute-Derma?
Our treatment plan addresses joint symptoms and skin appearance at the same time:
- Targeted biologic therapy (anakinra, canakinumab): our first choice for neutralizing IL-1. These drugs stop pus from forming in the joints and help ulcerated skin heal quickly.
- Anti-TNF-alpha agents (adalimumab, infliximab): particularly effective for controlling pyoderma gangrenosum and the accompanying severe acne.
- Intensive acne management: low-dose isotretinoin combined with biologic therapy to control oil production and prevent new cysts.
- Scar and skin repair at Haute-Derma: fractional CO2 laser, RF microneedling or intralesional scar injections to restore skin structure once inflammation has settled.
- Sterile joint drainage: ultrasound-guided aspiration of joint fluid during acute pus-filled flares to relieve pressure and prevent cartilage destruction.
